VivoSeq
Other

Pseudomonas Aeruginosa

1

Pipeline Programs↗

4

Active Trials↗

4

Companies Involved↗

Pseudomonas Aeruginosa is an early-stage landscape with 1 program across 4 companies. The most active players are AstraZeneca, Armata Pharmaceuticals, Inc., Gilead.

Intelligence

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

75/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AstraZeneca logo

AstraZeneca

1 program

Phase 2A

Armata Pharmaceuticals, Inc.

0 programs

PreclinicalGilead logo

Gilead

0 programs

PreclinicalP

Phaxiam Therapeutics

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 21

AZD0292

AstraZeneca

Phase 3
No programs
Approved
No programs

Analysis

Trial Status

15

clinical trials

Completed6 · 40%
Unknown status2 · 13%
Active, not recruiting2 · 13%
Enrolling by invitation1 · 7%
Withdrawn1 · 7%
No longer available1 · 7%
Other2 · 13%

Clinical Trials

Trial Activity

15 trials

A Phase IIb Randomized, Double-blind, Placebo-controlled, Parallel, Multidose Study to Evaluate the Efficacy, Safety, and PK of AZD0292 in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization
Recruiting·AstraZeneca logoAstraZeneca·Phase 2·NCT07088926·435 enrolled
Efficacy and Safety of 7 Versus 14 Days of Antibiotic Treatment for Pseudomonas Aeruginosa Bacteraemia
Active, not recruiting·FFundación Pública Andaluza para la gestión de la Investigación en Sevilla·Phase 4·NCT05210439·306 enrolled
Nebulised RESP30X Nitric Oxide Formulations in NCFB Patients With Pseudomonas Aeruginosa (Pa)
Active, not recruiting·TThirty Respiratory Limited·Phase 1/2·NCT06663176·60 enrolled
Pseudomonas Aeruginosa Injection Combined With Polyvinylpyrrolidone-Iodine in Immediate Breast Reconstruction Surgery With Implants
Enrolling by invitation·—·N/A·NCT07460297·100 enrolled
Study Assessing Safety and Immunogenicity of IC43 Vaccination Against Pseudomonas Aeruginosa in Healthy Volunteers
Completed·VValneva Austria GmbH·Phase 1·NCT00778388·157 enrolled
Macrolide Mediates Pulmonary Infection of Pseudomonas Aeruginosa
Completed·—·N/A·NCT02491723·71 enrolled
Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF
Completed·Gilead logoGilead·Phase 3·NCT01641822·107 enrolled
Study to Evaluate Arikayce™ in CF Patients With Chronic Pseudomonas Aeruginosa Infections
Completed·IInsmed Incorporated·Phase 3·NCT01315678·302 enrolled
Piperacillin-Tazobactam Continuous Versus Intermittent Infusion for Pseudomonas Aeruginosa
Completed·FFundación Pública Andaluza para la gestión de la Investigación en Sevilla·Phase 3·NCT01577368·76 enrolled
Pilot Trial of KB001 in Mechanically-Ventilated Patients Colonized With Pseudomonas Aeruginosa
Completed·HHumanigen, Inc.·Phase 1/2·NCT00691587·36 enrolled
Pivotal Study in VAP Suspected or Confirmed to be Due to Pseudomonas Aeruginosa
Terminated·PPolyphor Ltd.·Phase 3·NCT03409679·41 enrolled
Study to Evaluate Arikace™ in CF Patients With Chronic Infection Due to Pseudomonas Aeruginosa
Withdrawn·IInsmed Incorporated·Phase 3·NCT01315691
In Vitro Activity of Ceftolozane/Tazobactam and Imipenem/Relebactam in Clinical Isolates of Pseudomonas Aeruginosa and Enterobacterales Collected From Hematology and Oncology Patients
Unknown status·—·N/A·NCT04196608·1,005 enrolled
Individual Patient Expanded Access for AB-PA01, an Investigational Anti-Pseudomonas Aeruginosa Bacteriophage Therapeutic
No longer available·AArmata Pharmaceuticals, Inc.·N/A·NCT03395743
Evaluation of Phage Therapy for the Treatment of Escherichia Coli and Pseudomonas Aeruginosa Wound Infections in Burned Patients
Unknown status·PPhaxiam Therapeutics·Phase 1/2·NCT02116010

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)